Search

Search Results

• 

  Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

  R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni

  83-89

  09-09-2016

  Published: 9 September 2016

  1698

  PDF: 868

  IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 0

• Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience

  C. Botsios, P. Ostuni, S. Todesco

  44-51

  Published:

  1111

  PDF: 1708

• Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy

  G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini

  50-56

  Published:

  1078

  PDF: 720

• Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab

  A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, L. Punzi, S. Todesco

  121-126

  Published:

  1647

  PDF: 1654
• 

  A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy

  A. Notarnicola, F. Iannone, G. Lopalco, M. Covelli, G. Lapadula

  298-301

  17-03-2014

  Published: 17 March 2014

  2059

  PDF: 1014
• 

  Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

  F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro

  208-214

  06-11-2014

  Published: 6 November 2014

  2482

  PDF: 1396
• 

  Intra-articular therapy with tumor necrosis factor-α antagonists: an update

  S. Bello, C. Bonali, L. Serafino, C. Rotondo, N. Terlizzi, G. Lapadula

  257-263

  14-03-2014

  Published: 14 March 2014

  2401

  PDF: 1175
• 

  Infliximab as successful treatment option in a case of adenosine deaminase 2 deficiency

  M.B. Ates, S. Karup, S. Ugurlu

  19-12-2023

  Published: 19 December 2023

  1019

  PDF: 273
• 

  Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease

  L.B. Santos, J. Rigueira, A.P. Vilas

  163-165

  24-10-2019

  Published: 24 October 2019

  1231

  PDF: 763

• Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection - Reply

  M. Galeazzi

  112

  Published:

  724

  PDF: 574
• 

  Psoriatic arthritis: treatment strategies using biologic agents

  S. D'Angelo, C. Palazzi, I. Olivieri

  113-121

  05-06-2012

  Published: 5 June 2012

  1108

  PDF: 1133

• The treatment of recurrent uveitis with TNFα inhibitors

  P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula

  185-189

  Published:

  1686

  PDF: 2294

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  Published:

  1074

  PDF: 1070
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  Published: 9 November 2011

  1286

  PDF: 1190

• Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

  G. Lapadula

  22-29

  Published:

  721

  PDF: 1038
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  Published: 9 November 2011

  1906

  PDF: 1466

• Sustained response to infliximab treatment in two cases of early rheumatoid arthritis that has been maintained after drug withdrawal

  P. Caramaschi, S. Pieropan, A. Volpe, A. Carletto, L.M Bambara, D. Biasi

  221-223

  Published:

  737

  PDF: 1295

• Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab

  M. Gutierrez, A. Becciolini, C. Bertolazzi, L. Di Geso, M. Tardella, A. Ariani, E. Filippucci, W. Grassi

  221-224

  Published:

  1132

  PDF: 655

• Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab

  Giuseppe D'Alessandro, Maria Rosaria Bianco, Spiridon Politis, Celestino Ferrandina, Giuseppe Rossi, Emanuele Altomare

  59-61

  Published:

  870

  PDF: 849

• Diffused suberitrodermic psoriasis induced by infliximab

  V. Bruzzese

  328-331

  Published:

  831

  PDF: 1065

• Intra-articular therapy with infliximab in psoriatic arthritis: efficacy and safety in refractory monoarthritis

  S. Bello, C. Bonali, L. Serafino, P. Di Giuseppe, A. Minosi, N. Terlizzi

  46-50

  Published:

  1059

  PDF: 1277

• Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

  Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini

  31-38

  Published:

  1744

  PDF: 2482

• Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment

  M. Di Gangi, R. Foti, R. Leonardi, C. Leonetti, P. Castellino

  169-172

  Published:

  917

  PDF: 844

• Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

  F.I. Gorial, N.I. Awadh, A. Al-Shakarchi, G. Al-Gburi

  30-10-2024

  Published: 30 October 2024

  273

  PDF: 118

• Effects of TNF antagonists on immune and neuroendocrine system

  G. Valesini, M. Cutolo

  3-7

  Published:

  1097

  PDF: 710

• TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade

  F. Ursini

  254-259

  Published:

  1289

  PDF: 2143

• A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

  Giovanna Cuomo, Gabriella Molinaro, Giovanni La Montagna, Sergio Migliaresi, Gabriele Valentini

  22-25

  Published:

  1455

  PDF: 1939
• 

  Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

  G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

  75-78

  27-05-2013

  Published: 27 May 2013

  2858

  PDF: 851

• Anti-TNFa treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

  I. Cavazzana, F. Franceschini, E. Danieli, M. Frassi, M. Vianelli, R. Gorla, P. Airò, R. Cattaneo

  267-272

  Published:

  995

  PDF: 1547

• Infliximab treatment in a case of rheumatoid scleromalacia perforans

  R. Herrera-Esparza, E. Avalos-Diaz

  212-215

  Published:

  1139

  PDF: 930

• Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis

  C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi

  32-37

  Published:

  1550

  PDF: 707

• Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

  R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

  107-117

  Published:

  1815

  PDF: 1067

• Approved indications and other possible utilizations of anti-TNFa biologic drugs

  W. Grassi, C. Montecucco

  30-33

  Published:

  1078

  PDF: 843

• Are there any positive effects of TNF-alpha blockers on bone metabolism?

  B. Seriolo, S. Paolino, A. Sulli, M. Cutolo

  199-205

  Published:

  1146

  PDF: 1074

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  Published:

  926

  PDF: 2904

• Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?

  A.R. Giardina, A. Accardo-Palumbo, F. Ciccia, A. Ferrante, A. Principato, R. Impastato, G. Triolo

  21-26

  Published:

  1348

  PDF: 1063

• Biologic therapy with anti-TNFa in rheumathoid atrhritis

  G. Ferraccioli

  17-21

  Published:

  722

  PDF: 629

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  Published:

  1270

  PDF: 894

• Differences in pharmacology of tumor necrosis factor (TNF) antagonists

  U. Fiocco, S. Bombardieri

  8-16

  Published:

  1083

  PDF: 1724

• Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

  C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

  224-235

  Published:

  1049

  PDF: 2295